Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Seen Running Too Hot, Let’s Look At This More Closely
Currently, there are 399.15M common shares owned by the public and among those 330.56M shares have been available to trade. The company’s stock has a 5-day price change of 11.13% and 12.87% over the past three months. RXRX shares are trading -24.36% year to date (YTD), with the 12-month market performance down to -3.99% lower. […]
Recursion Pharmaceuticals Inc (NASDAQ: RXRX): Stock That Needs Special Handling
Currently, there are 399.15M common shares owned by the public and among those 330.56M shares have been available to trade. The company’s stock has a 5-day price change of 10.61% and 9.77% over the past three months. RXRX shares are trading -32.09% year to date (YTD), with the 12-month market performance down to -13.61% lower. […]
Recursion Pharmaceuticals Inc (RXRX): A Great Stock For Handling Current Market Conditions?
Currently, there are 399.15M common shares owned by the public and among those 330.56M shares have been available to trade. The company’s stock has a 5-day price change of 0.19% and 13.55% over the past three months. RXRX shares are trading -29.03% year to date (YTD), with the 12-month market performance down to -21.89% lower. […]
Gains May Be On The Menu For Recursion Pharmaceuticals Inc (NASDAQ: RXRX)
Currently, there are 399.15M common shares owned by the public and among those 310.64M shares have been available to trade. The company’s stock has a 5-day price change of -2.41% and -0.38% over the past three months. RXRX shares are trading -29.36% year to date (YTD), with the 12-month market performance down to -22.04% lower. […]
Gains May Be On The Menu For Recursion Pharmaceuticals Inc (NASDAQ: RXRX)
Currently, there are 399.15M common shares owned by the public and among those 310.65M shares have been available to trade. The company’s stock has a 5-day price change of 0.00% and -15.75% over the past three months. RXRX shares are trading -46.38% year to date (YTD), with the 12-month market performance down to -25.59% lower. […]
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Seen Running Too Hot, Let’s Look At This More Closely
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of -2.71% and -22.38% over the past three months. RXRX shares are trading -46.32% year to date (YTD), with the 12-month market performance down to -25.59% lower. […]
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Is Getting Increasingly Hard To Ignore
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of -10.38% and -22.52% over the past three months. RXRX shares are trading -27.22% year to date (YTD), with the 12-month market performance down to -42.66% lower. […]
Value Hunters: Look To Recursion Pharmaceuticals Inc (RXRX)
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of 31.34% and -16.69% over the past three months. RXRX shares are trading -18.79% year to date (YTD), with the 12-month market performance down to -34.72% lower. […]
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Hogging The Spotlight Today
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of 0.84% and -44.34% over the past three months. RXRX shares are trading -38.17% year to date (YTD), with the 12-month market performance down to -53.50% lower. […]
Reviewing The Case For Recursion Pharmaceuticals Inc (RXRX) Going Higher
Currently, there are 399.15M common shares owned by the public and among those 310.78M shares have been available to trade. The company’s stock has a 5-day price change of -2.66% and -46.07% over the past three months. RXRX shares are trading -35.06% year to date (YTD), with the 12-month market performance down to -53.10% lower. […]